| Literature DB >> 24822110 |
Shuidong Feng1, Hongyan Ling1, Hui Guo1, Lingling Tong1, Guobin Hu1, Li Liao1, Xueying Lv1, Hongzhuan Tan1, Yimou Wu1.
Abstract
ERBB2 mutations have been reported to occur in a subset of patients with lung adenocarcinomas or lung squamous cell carcinomas for some ethnicities, but it is unclear for Chinese patients with lung squamous cell carcinomas up to now. We retrospectively evaluated the status of ERBB2 mutations in a large cross-sectional cohort of 212 Chinese patients with non-small cell lung cancer (NSCLC) diagnosed in several hospitals from southern China during a time period of 1.5 years by polymerase chain reaction (PCR)-based direct sequencing and PCR-single strand conformation polymorphism (PCR-SSCP) analysis. ERBB2 mutation was found in 1 of 49 lung adenocarcinomas (2.0%) and none in lung squamous cell carcinomas and lung adenosquamous carcinomas. It implies the occurrence of ERBB2 mutations is infrequent in Chinese patients with NSCLC, especially in lung squamous cell carcinomas.Entities:
Keywords: ERBB2/HER2; molecular; mutation; non-small cell lung cancer (NSCLC)
Year: 2014 PMID: 24822110 PMCID: PMC4015026 DOI: 10.3978/j.issn.2072-1439.2014.03.20
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895